273 related articles for article (PubMed ID: 29151523)
1. Neuroendocrine Carcinoma of the Stomach: A Response to Combination Chemotherapy Consisting of Ramucirumab Plus Paclitaxel.
Matsubara Y; Ando T; Hosokawa A; Mihara H; Takagi H; Nakata N; Yoshita H; Nanjo S; Kajiura S; Fujinami H; Sugiyama T
Intern Med; 2018 Mar; 57(5):671-675. PubMed ID: 29151523
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).
Jung M; Ryu MH; Oh DY; Kang M; Zang DY; Hwang IG; Lee KW; Kim KH; Shim BY; Song EK; Sym SJ; Han HS; Park YL; Kim JS; Lee HW; Lee MH; Koo DH; Song HS; Lee N; Yang SH; Choi DR; Hong YS; Lee KE; Maeng CH; Baek JH; Kim S; Kim YH; Rha SY; Cho JY; Kang YK
Gastric Cancer; 2018 Sep; 21(5):819-830. PubMed ID: 29427038
[TBL] [Abstract][Full Text] [Related]
3. [Second-line treatment for metastatic or locally advanced gastric cancer].
Li KC; Cheng SY; Du J; Li J
Zhonghua Zhong Liu Za Zhi; 2016 Oct; 38(10):721-724. PubMed ID: 27784452
[TBL] [Abstract][Full Text] [Related]
4. Treatment with Ramucirumab-paclitaxel in a metastatic gastric cancer patient undergoing hemodialysis: A case report.
Yang MJ; Choi YJ; Kim HJ; Kim DY; Seol YM
Medicine (Baltimore); 2021 Feb; 100(7):e24795. PubMed ID: 33607838
[TBL] [Abstract][Full Text] [Related]
5. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
[TBL] [Abstract][Full Text] [Related]
6. Partial response of metastatic cardia neuroendocrine carcinoma with the combined therapy involving PD-1 blockade after failed multi-line chemotherapies: a case report and literature review.
Yang Y; Xu H; Zhang L; Bai L; Zhu H; Li Q
Anticancer Drugs; 2022 Feb; 33(2):214-219. PubMed ID: 34620744
[TBL] [Abstract][Full Text] [Related]
7. [A Case of Gastric Cancer with Peritoneal Dissemination Effectively Treated with Ramucirumab and Paclitaxel].
Seo S; Suzuki T; Misumi T; Tashiro H
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1305-1307. PubMed ID: 29394615
[TBL] [Abstract][Full Text] [Related]
8. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
9. [A Case of Lymph Nodes Metastases of Gastric Neuroendocrine Carcinoma Treated with Nivolumab and Showing Complete Response].
Wada N; Takachi K; Shirosaki Y; Fujiwara M; Fukuda N; Matsuura Y; Munakata K; Takiuchi D; Hama N; Ota H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1546-1547. PubMed ID: 38303336
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
[TBL] [Abstract][Full Text] [Related]
11. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
12. [A case of gastric cancer with peritoneal dissemination who achieved long survival by successive treatments with S-1 in combination with CDDP, paclitaxel and irinotecan].
Seshimo K; Kanagawa T; Yamashita Y; Oishi M; Kodera M; Yamamura M; Katoh H; Ikeda H; Yokomichi N; Kobayashi K; Takita K
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1741-4. PubMed ID: 19838039
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
Di Bartolomeo M; Niger M; Morano F; Corallo S; Antista M; Tamberi S; Lonardi S; Di Donato S; Berardi R; Scartozzi M; Cardellino GG; Di Costanzo F; Rimassa L; Luporini AG; Longarini R; Zaniboni A; Bertolini A; Tomasello G; Pinotti G; Scagliotti G; Tortora G; Bonetti A; Spallanzani A; Frassineti GL; Tassinari D; Giuliani F; Cinieri S; Maiello E; Verusio C; Bracarda S; Catalano V; Basso M; Ciuffreda L; De Vita F; Parra HS; Fornaro L; Caporale M; de Braud F; Pietrantonio F
BMC Cancer; 2019 Mar; 19(1):283. PubMed ID: 30922323
[TBL] [Abstract][Full Text] [Related]
14. Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer.
Muro K; Oh SC; Shimada Y; Lee KW; Yen CJ; Chao Y; Cho JY; Cheng R; Carlesi R; Chandrawansa K; Orlando M; Ohtsu A
J Gastroenterol Hepatol; 2016 Mar; 31(3):581-9. PubMed ID: 26317322
[TBL] [Abstract][Full Text] [Related]
15. [A case of gastric neuroendocrine cell carcinoma successfully treated by neoadjuvant chemotherapy].
Onoyama H; Iwasaki Y; Ohashi M; Iwanaga T; Ohinata R; Maeda Y; Omuro Y; Sasaki E; Shimoyama T; Tateishi Y
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2131-3. PubMed ID: 22202306
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study.
De Vita F; Borg C; Farina G; Geva R; Carton I; Cuku H; Wei R; Muro K
Future Oncol; 2019 Aug; 15(23):2723-2731. PubMed ID: 31234645
[No Abstract] [Full Text] [Related]
17. [An Elderly Case of Recurrent Neuroendocrine Carcinoma of the Stomach Treated with Ramucirumab].
Koizumi N; Kobayashi H; Takagi T; Fukumoto K
Gan To Kagaku Ryoho; 2018 Mar; 45(3):557-559. PubMed ID: 29650937
[TBL] [Abstract][Full Text] [Related]
18. Ramucirumab: A Review in Advanced Gastric Cancer.
Greig SL; Keating GM
BioDrugs; 2015 Oct; 29(5):341-51. PubMed ID: 26341713
[TBL] [Abstract][Full Text] [Related]
19. Successful Conversion Surgery for Advanced Gastric Cancer With Multiple Liver Metastases Following Ramucirumab Plus Paclitaxel Combination Treatment.
Namikawa T; Marui A; Yokota K; Fujieda Y; Munekage M; Uemura S; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
In Vivo; 2021; 35(5):2929-2935. PubMed ID: 34410989
[TBL] [Abstract][Full Text] [Related]
20. The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
Roviello G; Petrioli R; Rosellini P; Multari AG; Conca R; Paganini G; Chiriacò G; Aieta M
Invest New Drugs; 2019 Jun; 37(3):524-530. PubMed ID: 30687871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]